•We
have generated a panel of highly specific, dual antagonist monoclonal
anti-ADAM8 antibodies; each antibody can simultaneously inhibit the MP and DI
activities.
•Two
lead therapeutic candidates, ADP2 and ADP13, significantly reduce tumor growth
and metastasis and improve survival in TNBC mouse models when given as
monotherapies.
•These
antibodies also dramatically enhance treatment response when added to
chemotherapy.
•In
the future, we plan to expand to other ADAM8-driven oncology indications beyond
TNBC